Dual time-point FDG PET/CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area by Sathekge, Mike Machab et al.
598 September 2010, Vol. 100, No. 9  SAMJ
ORIGINAL ARTICLES
Dual time-point FDG PET/CT for differentiating benign from malignant 
solitary pulmonary nodules in a TB endemic area
Mike Machaba Sathekge, Alex Maes, Hans Pottel, Anton Stoltz, Christophe van de Wiele
Objective.  Fluorodeoxyglucose (FDG)-positron emission tomography 
(PET) is an accurate non-invasive imaging test for differentiating 
benign from malignant solitary pulmonary nodules (SPNs). We 
aimed to assess its diagnostic accuracy for differentiating benign from 
malignant SPNs in a tuberculosis (TB)-endemic area. 
Methods. Thirty patients, 22 men and 8 women, mean age 60 
years, underwent dual time point FDG-PET/computed tomography 
(CT) imaging, followed by histological examination of the SPN. 
Maximum standard uptake values (SUVmax) with the greatest 
uptake in the lesion were calculated for two time points (SUV1 
and SUV2), and the percentage change over time per lesion was 
calculated (%DSUV). Routine histological findings served as the 
gold standard. 
Results. Histological examination showed that 14 lesions were 
malignant and 16 benign, 12 of which were TB. SUVmax for benign 
and malignant lesions were 11.02 (standard deviation (SD) 6.6) v. 
10.86 (SD 8.9); however, when tuberculomas were excluded from 
the analysis, a significant difference in mean SUV1max values 
between benign and malignant lesions was observed (p=0.0059). 
Using an SUVmax cut-off value of 2.5, a sensitivity of 85.7% and 
a specificity of 25% was obtained. Omitting the TB patients from 
analysis resulted in a sensitivity of 85.7% and a specificity of 100%. 
Mean %DSUV of benign lesions did not differ significantly from 
mean %DSUV of malignant lesions (17.1% (SD 16.3%) v. 19.4% 
(SD 23.7%)). Using a cut-off of %DSUV >10% as indicative of 
malignancy, a sensitivity of 85.7% and a specificity of 50% was 
obtained. Omitting the TB patients from the analysis yielded a 
sensitivity of 85.7% and a specificity of 75%. 
Conclusion. Our findings suggest that FDG-PET cannot 
distinguish malignancy from tuberculoma and therefore cannot 
reliably be used to reduce futile biopsy/thoracotomy.
S Afr Med J 2010; 100: 598-601.
Fluorodeoxyglucose (FDG)-positron emission tomography (PET) has 
proved to be an accurate non-invasive imaging test for differentiating 
benign from malignant solitary pulmonary nodules (SPNs).1-4 
However, some types of cancers, e.g. carcinoid tumours and broncho-
alveolar carcinoma, have low FDG uptake that can give false-negative 
results. Many benign processes such as infection, inflammation and 
granulomatous diseases, especially tuberculosis (TB), present as SPNs 
with enhanced FDG uptake leading to false-positive findings.5,6 Since 
TB is more prevalent in South Africa than in developed countries, it 
may be anticipated that the accuracy of FDG-PET in differentiating 
benign from malignant SPNs will be significantly worse owing to a 
drop in specificity.
Over time the uptake of FDG continues to increase in malignant 
lesions, whereas it decreases or remains stable  in benign lesions.7-9 It 
was therefore deduced that dual time-point imaging might further 
improve the accuracy of FDG-PET to distinguish benign from 
malignant SPNs. However, a study of 27 patients suffering from 
SPN using delayed FDG-PET imaging in a tuberculosis endemic 
region such as Taiwan, found no significant difference in mean SUV, 
maximal SUV and retention index between benign and malignant 
solitary pulmonary nodules with an initial mean SUV less than 2.5; 
the area under the receiver operating curve did not differ from 0.5.10 
Accordingly, we aimed to assess the diagnostic accuracy of dual-time 
point FDG-PET imaging in differentiating benign from malignant 
SPNs in a region with a high prevalence of TB.
Patients and methods
The study was approved by the Ethics Committee of the University 
of Pretoria. Thirty consecutive patients were prospectively included 
after giving written informed consent. There were 22 men and 8 
women. SPNs were all incidentally detected on chest radiographs and 
computed tomography (CT) scans done for clinical indications such 
as dyspnoea, chest pain, cough and pre-operative radiographs. The 
patients underwent FDG-PET imaging followed by biopsy or surgical 
removal of the SPN. Routine histological examination of the biopsy 
material or surgical specimens served as the gold standard. 
Dual-phase FDG-PET/CT scanning
The patients fasted for a minimum of 4 hours before the FDG-PET/
CT whole-body scan. The [18F]-FDG was administrated intrave-
nously using the formula [(body weight/10)+1)]*37 MBq. Between 
injection and scanning they were asked to remain still, covered with 
a blanket and without auditory stimuli, for at least 45 minutes to 
avoid uptake of the radiotracer at physiological sites excited by these 
stimuli, which can result in artefacts that have false-positive inter-
pretations. During this activation phase, patients were instructed to 
drink 1 litre of contrast material (barium diluted in water). 
The images were acquired in a three-dimensional mode using a 
PET/CT Biograph 40 (Siemens Medical Solutions). Forty-five minutes 
after injection, the first whole-body scan, with a 3-minute emission 
Department of Nuclear Medicine, Steve Biko Academic Hospital and University of 
Pretoria  
Mike Machaba Sathekge, MB ChB, MMed (Nucl Med), PhD
Department of Nuclear Medicine, AZ Groeninge, Kortrijk, Belgium 
Alex Maes, MD, PhD
Subfaculty of Medicine, Catholic University Leuven, Campus Kortrijk, Belgium  
Hans Pottel, PhD  
Division of Infectious Diseases, University of Pretoria 
Anton Stoltz, MB ChB, MMed (Int Med), PhD
Department of Nuclear Medicine, University Hospital Ghent, Ghent, Belgium 
Christophe van de Wiele, MD, PhD
Corresponding author: M M Sathekge (mike.sathekge@up.ac.za)
599September 2010, Vol. 100, No. 9  SAMJ
ORIGINAL ARTICLES
scan for each of 9 bed positions, was done from the skull base to the 
pelvis. Patients were asked not to move while on the scanning table, 
and a second whole-body scan was started from 120 minutes after 
injection. For CT imaging, contrast enhancement was achieved by 
intravenous administration of 100 ml of non-ionic contrast material 
(Ultravist) at a rate of 2 ml/s. Matrix size was 512×512. 
Images were reconstructed with and without attenuation correction 
(CT based) using OSEM (ordered subset expectation maximisation) 
yielding axial, sagittal and coronal slices. The FDG-PET images 
obtained were analysed by two experienced nuclear medicine 
specialists, blinded to the results obtained by morphological imaging. 
Disagreements were resolved by consensus.
Quantitative analysis
All images were initially evaluated visually. Foci of intense uptake 
exceeding the uptake of the surrounding mediastinal/normal 
structures and of nodular appearance were considered abnormal. 
The semi-quantitative analysis of the degree of uptake of the 
lesions characterised by the FDG-PET/CT scans was based on the 
standard uptake value (SUV). The SUV represents the activity of the 
radiotracer in a topographic region of the body image or volume of 
interest normalised to the weight of the patient and to the quantity 
of radiotracer administered, hence the formula: SUV = radiotracer 
activity × weight of the patient/injected dose, which characterises the 
rela tive concentration of the radiotracer in the lesion of interest.
We used the SUV for the pixel with the greatest uptake in the 
lesion (maximum pixel SUV). SUVmax values were obtained for all 
lesions identified by drawing manually defined regions of interest 
on the attenuation-corrected early and delayed axial images. The 
corresponding CT image was used as anatomical landmark. Regions 
of interest (ROI) were overlaid onto the lesions of scans 1 and 2 
axial slices through direct visual assessment of the lesions on the 
CT scan and subsequent identification of the corresponding area 
on PET scans 1 and 2. In tumour lesions that extended over several 
slices in the craniocaudal direction, the ROI was placed in the mid-
portion of the lesion where the maximal SUV was measured. In case 
no discernable uptake was present on either PET scan, ROIs were 
drawn in the presumed location that corresponded best with the 
radiographic density. The retention index was defined as follows: 
(maximal SUV on delayed images - maximal SUV on early images)/
maximal SUV on early images %. Hence from the SUVmax values 
obtained, percentage change in SUVmax from early to delayed images 
was calculated using the following formula:
%DSUVmax = (SUV maxD-SUVmaxE)/SUVmaxE × 100
SUV1max values and %DSUVmax values were used for further 
analysis.
Statistical analysis
Statistical analysis was performed using SPSS version 15.0. 
Differences in SUVmax between benign and malignant SPNs were 
assessed using a two-tailed unpaired t-test. Differences in SUVmax 
values on early imaging as well as percentage changes in SUVmax 
between different underlying pathologies were assessed using analysis 
of variance and Kruskal-Wallis test, followed by Dunn’s multiple 
comparison test. Statistical significance was defined as p<0.05.
Results
Results are set out in Table I.
The mean age of the patients was 60 years (range 37 - 84 years). 
There were 8 women and 22 men. On histological examination, 
SPNs proved to be benign in 16 patients; there were 12 tuberculomas, 
1 hamartoma, 2 rheumatoid nodules and 1 fibrous lesion. In the 
remaining 14 patients SPNs were malignant (Table I). The diameter 
of the SPNs was not significantly different between benign (mean 
1.9, standard deviation (SD) 0.2) and malignant lesions (mean 1.9, 
SD 0.3) (p= 0.5). 
Malignant versus benign
Mean SUV1max values of the benign lesions did not differ significantly 
from those of the malignant lesions (11.02 (SD 6.6) v. 10.86 (SD 8.9)). 
The high overlap in SUV mean values between the two groups limits 
the clinical value of FDG-PET/CT in a TB-endemic area (Fig. 1).
However, when tuberculomas were excluded from the analysis, 
a significant difference in mean SUV1max values between benign 
and malignant lesions was observed (p=0.0059). Using an SUVmax 
cut-off value of 2.5, as reported in literature, a sensitivity of 85.7% 
and a specificity of 25% was obtained.11,12 Omitting the tuberculomas 
from this analysis resulted in a sensitivity of 85.7% and a specificity 
of 100%, results comparable to other reports. Receiver operating 
characteristic (ROC) curve analysis (Fig. 2) performed to try to 
identify a single cut-off did not display discriminatory power when 
tuberculomas were included (area under the curve (AUC)=0.558, 
p=0.224) owing to the very poor specificity.
Mean %DSUV of benign lesions did not differ significantly from 
mean %DSUV of malignant lesions (17.1% (SD 16.3%) v. 19.4% 
(SD 23.7%)). Using a cut-off of  >10% as indicative of malignancy, 
as reported in the literature, a sensitivity of 85.7% and a specificity 
of 50% were obtained. Omitting the tuberculoma patients from the 
analysis yielded a sensitivity of 85.7% and a specificity of 75%.
Malignant lesions versus tuberculomas versus 
other benign conditions
Median SUV1max values of malignant lesions, tuberculomas and 
other benign conditions were respectively 6.7 (25 - 75 percentile: 3.2 
- 13.1), 7.6 (25 - 75 percentile: 5.9 - 12.7) and 1.4 (25 - 75 percentile: 
0.9 - 1.8). SUV1 values of tuberculomas were significantly higher 
than those of other benign lesions (p<0.05) (Fig. 3). 
Median %DSUV values of malignant lesions, tuberculomas and 
other benign conditions were respectively 19.5% (25 - 75 percentile: 
12.9 - 41.5), 13% (25 - 75 percentile: 5.9 - 22.7%) and -11.3% (25 - 75 
percentile: -25.3 - 10.1). %DSUV values did not differ significantly 
between TB and malignant lesions (Fig. 4). 
Finally, plotting SUV1 over SUV2 values per patient, indicating 
the rate of increase in SUVmax, graphically illustrates that the rate 
of increase in SUVmax is not different between tuberculomas and 
malignant lesions (Fig. 5).
Discussion
Few studies have assessed the potential of dual time-point imaging 
for differentiating malignant from benign SPNs. Using a 10% increase 
in delayed SUV for pulmonary malignancy, Matthies et al. claimed an 
increase in sensitivity from 80% to 100% and a decrease in specificity 
from 94% to 89%.7 In this series, 36 patients were studied and the 
benign character of SPNs was established by long-term follow-up in 
the majority of patients. Using the same threshold, Xiu et al. found 
that in patients presenting with SPNs with an initial SUVmax below 
2.5, the dual technique increased the accuracy of PET from 65.2% to 
84.8%, largely because of an increase of sensitivity versus only minor 
drop in specificity.13 Chen et al., reporting on patients cumulatively 
presenting with 31 lesions in a geographic region with epidemic 
granulomatous disease, including tuberculosis,  found that delayed 
FDG PET imaging was not useful for differentiating benign from 
malignant pulmonary nodules with an initial mean SUV less than 
2.5.10 Our data extend these findings to the global patient population 
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presenting with SPNs in a TB-endemic environment such as South 
Africa, and confirms the findings even on patients with an initial 
SUV above 2.5. Hence FDG-PET is unable to distinguish malignancy 
from TB and therefore cannot be reliably used as a tool to reduce 
futile biopsy/thoracotomy in these patients. 
It has been suggested that in tumours an increased ratio of 
hexokinase to glucose-6-phosphatase results in gradual accumulation 
Table I. Patient characteristics
     Lesion size 
Patient No. Age          Sex  (cm)/location    Histopathology         SUV1  SUV2     %DSUV
1  37.0          M  2.3/RML         Adeno Ca          5.4  7.8       44.4
2  53.6          M  1.9/RLL  Rheumatoid nodule          1.3  1.1      -15.4
3  79.4          M  2.2/LLL              TB           11.1  16.5       48.6
4  67.1          M  1.8/RML  Malignant cells/Ca          1.6  1.4      -12.5
5  54.1          M  2.1/RUL         Adeno Ca          8.6  9.9       15.1
6  63.5          M  1.9/LUL         Adeno  Ca          3.4  4.8       41.2
7  44.6          M  1.5/RUL  Malignant cells/Ca          2.7  3.1       14.8
8  69.4          M  1.4/RLL        Sqamous cell           6.5  8.1       24.6
9  39.1          M  1.7/LLL             TB           9.5  10.7       12.6
10  51.8          F  2.1/LUL           BAC           1.8  1.1      -38.9
11  70.8          M  2.0/LUL             TB           6.6  9.8       48.5
12  58.0          F  1.6/RML       Harmatoma          1.9  2.2       15.8
13  56.3          F  1.8/RUL    Melanoma mets          6.8  7.6       11.8
14  84.3          M  2.1/RML             TB           7.9  9.5       20.3
15  66.9          M  1.7/RLL  No malignant cells          1.4  1.3      -7.1
16  61.3          F  2.3/LUL        Adeno Ca          14.4  21.8       51.4
17  61.8          M  1.8/RUL        Adeno Ca          12.6  15.5       23.0
18  62.7          M  1.7/RUL             TB           22.4  25.4       13.4
19  68.4          F  2.4/LUL        Adeno Ca          25.6  29.7       16.0
20  84.1          M  1.9/RML        Adeno Ca          9.6  12.0       25.0
21  78.3          M  1.5/RML  Rheumatoid nodule          0.7  0.5      -28.6
22  61.7          M  1.9/RUL            TB           3.5  4       14.3
23  64.1          M  1.7/LUL        Adeno Ca          3.8  4.3       13.2
24  68.7          M  2.3/RUL            TB           5.7  6       5.3
25  50.0          F  2.1/LUL            TB           13.2  16.3       23.5
26  47.5          F  1.7/LLL            TB           2.6  2.5      -3.8
27  85.8          M  2.9/RUL        Adeno Ca          17.5  24.9       42.3
28  59.0          M  2.0/RML            TB           15.9  16.7       5.0
29  41.4          M  1.6/RUL            TB           6.4  6.9       7.8
30  37.8          F  1.7/RLL            TB           7.2  7.9       9.7
M = male; F = female; SPN = solitary pulmonary nodule; SUV = standardised uptake value; %DSUV = percentage change in SUV; RML = right middle lobe; RUL = right upper lobe; RLL = right 
lower lobe; LUL = left upper lobe; LLL = left lower lobe; Ca = carcinoma; BAC = broncho-alveolar cell carcinoma; Mets = metastases.
Fig. 1. A 50-year-old woman with a left upper lobe nodule which is FDG 
avid on the early images (SUV1=13.2) and delayed images (SUV=16.3), 
and a retention index of 23.5%. These features are indistinguishable from 
TB, although the patient was proven to have TB. 
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Fig. 2. ROC curve (AUC = area under the curve; SE = standard error; S = 
sensitivity; SP = specificity).
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of FDG and therefore in a further increase in SUV on delayed 
imaging.14 In contrast, high levels of glucose-6-phosphatase are 
expressed by mononuclear cells which represent the major cell 
population in chronic inflammation and infection, causing rapid 
clearance of FDG and subsequently a low ratio of hexokinase to 
glucose-6-phosphatase.9 Our findings do not necessarily contradict 
this hypothesis. Rather they may point towards other cells or 
Myocobacterium tuberculosis itself as being responsible for the 
high, progressive accumulation of FDG in tuberculomas over 
time.15 Enzymes involved in glycosidic bond synthesis represent 
more than 1% of all open-reading-frame genes in M. tuberculosis, 
emphasising the relevance of this group of enzymes for their 
physiology and pathogenicity. More specifically, high levels of glucose 
are required to construct their unique, impermeable mycobacterial 
wall, characterised by an outer layer of mycolic acids, containing 
among others methylglucose lipopolysaccharides.15 Further research 
is needed to unravel this finding.
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Fig. 3. Boxplots showing the distribution of  SUV1 values for tuberculoma 
(TB) and other benign and malignant lesions.
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Fig. 4. Boxplots showing the distribution of  RelSUV (= percentage change from 
SUV1 to SUV2) for tuberculoma (TB), other benign and malignant lesions.
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Fig. 5. SUV1 over SUV2 plot per patient, indicating that the rate of increase 
in SUVmax does not differ between tuberculoma and malignant lesions.
